US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say

CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.

FDA entrance sign 2016

A restructuring of staff within the US FDA to strengthen the Oncology Center of Excellence (OCE) is one of the primary changes that advocates want to see in the agency's intercenter institute.

At an OCE listening session March 15, several external stakeholders commented to FDA staff that they would like to see...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet